37813-30-2

Basic information

• Product Name: 1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester
• Synonyms: 1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester;1-Boc-4-Hydroxy-L-Proline Ethyl Ester;Boc-L-Hydroxy-Proline Ethyl Ester;(2S,4R)-4-Hydroxy-1,2-pyrrolidinedicarboxylic acid 1-tert-butyl 2-ethyl ester;1-Boc-L-hydroxyproline ethyl ester;(2S,4R)-1-BOC-4-HYDROXYPYRROLIDINE-2-CARBOXYLIC ACID ETHYL ESTER;(2S-trans)-4-Hydroxy-1,2-pyrrolidinedicarboxylic acid 1-(1,1-dimethylethyl) 2-ethyl ester;1-tert-Butoxycarbonyl-4R-hydroxy-L-proline ethyl ester
• CAS NO: 37813-30-2
• Molecular Formula: C₁₂H₂₁NO₅
• Molecular Weight: 259.29884
• Mol File: 37813-30-2.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 350.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.189±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 14.30±0.40(Predicted)
• CAS DataBase Reference: 1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester(37813-30-2)
• EPA Substance Registry System: 1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester(37813-30-2)

Safety Data

• Hazardous Substances Data: 37813-30-2(Hazardous Substances Data)

Usage

General Description

1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester is a chemical compound with the molecular formula C13H23NO6. It is a derivative of proline, an amino acid, and is used in organic synthesis and peptide chemistry. The tert-butoxycarbonyl (Boc) group acts as a protective group for the hydroxy and amino groups of the proline, allowing for specific reactions to occur without interference from these groups. The ethyl ester group also provides stability and protection to the molecule. Overall, 1-tert-butoxycarbonyl-4-hydroxy-L-proline ethyl ester is a valuable tool in the synthesis of complex organic molecules and peptides.

Upstream product

• 1070-19-5 N-(tert-butyloxycarbonyl) azide 
• 33996-30-4 trans-4-hydroxy-L-proline ethyl ester hydrochloride 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 
• 61478-25-9 (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid ethyl ester 
• 64-17-5 ethanol 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 
• 74-96-4 ethyl bromide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 51-35-4 4R-4-hydroxyproline 
• 75-03-6 ethyl iodide 

Downstream Products

• 88043-21-4 (2S,4R)-4-(toluene-4-sulfonyloxy)-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 502442-64-0 ethyl (2S,4S)-N-tert-butyloxycarbonyl-4-tert-butyldiphenylsiloxyprolinate 
• 1023754-67-7 4-(3-benzoyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-2-[(tert-butoxycarbonylmethyl-methyl-amino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 887923-75-3 2-[(tert-butoxycarbonylmethyl-methyl-amino)-methyl]-4-(tert-butyl-diphenyl-silanyloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 887923-73-1 (2S,4S)-tert-butyl 4-(tert-butyldiphenylsilyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 887923-74-2 2-bromomethyl-4-(tert-butyl-diphenyl-silanyloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 74929-92-3 C₃₄H₃₅⁽²⁾H₂NO₂P₂ 
• 215918-51-7 (2S,4R)-4-benzyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 109953-95-9 tert-butyl (2S,4R)-4-(benzyloxy)-2-(hydroxymethyl)pyrrolidine-1-carboxylate 
• 191280-88-3 (2S,4S)-tert-butyl 4-hydroxy-2-(hydroxymethyl)pyrrolidine-1-carboxylate 

Relevant articles and documents

Rational Drug Design of Topically Administered Caspase 1 Inhibitors for the Treatment of Inflammatory Acne

The use of an interleukin β antibody is currently being investigated in the clinic for the treatment of acne, a dermatological disorder affecting 650M persons globally. Inhibiting the protease responsible for the cleavage of inactive pro-IL1β into active IL-1β, caspase-1, could be an alternative small molecule approach. This report describes the discovery of uracil 20, a potent (38 nM in THP1 cells assay) caspase-1 inhibitor for the topical treatment of inflammatory acne. The uracil series was designed according to a published caspase-1 pharmacophore model involving a reactive warhead in P1 for covalent reversible inhibition and an aryl moiety in P4 for selectivity against the apoptotic caspases. Reversibility was assessed in an enzymatic dilution assay or by using different substrate concentrations. In addition to classical structure-activity-relationship exploration, topical administration challenges such as phototoxicity, organic and aqueous solubility, chemical stability in solution, and skin metabolic stability are discussed and successfully resolved.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

HYDROGEN CHLORIDE SALT OF A SUBSTITUTED 5-OXAZOL-2-YL-QUINOLINE COMPOUND AND A PROCESS FOR THE PRODUCTION THEREOF

The present invention relates to the compound of the Formula I: and to methods of treating upper and lower obstructive airway diseases using said compound, to formulations comprising it, and to a particular crystalline form and processes of synthesis of the crystalline form. IM=105109